

Martin K Bakht

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1822356/publications.pdf>

Version: 2024-02-01

23
papers

476
citations

759233

12
h-index

713466

21
g-index

28
all docs

28
docs citations

28
times ranked

612
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. <i>Endocrine-Related Cancer</i> , 2019, 26, 131-146.	3.1	98
2	Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for ¹⁸ F-FDG Imaging of PSMA-Suppressed Tumors. <i>Journal of Nuclear Medicine</i> , 2020, 61, 904-910.	5.0	52
3	Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges. <i>Nuclear Medicine and Molecular Imaging</i> , 2017, 51, 202-211.	1.0	45
4	Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. <i>Nature Communications</i> , 2021, 12, 3372.	12.8	45
5	Scope of Nanotechnology-based Radiation Therapy and Thermo-therapy Methods in Cancer Treatment. <i>Current Cancer Drug Targets</i> , 2012, 12, 998-1015.	1.6	31
6	Internal radiotherapy techniques using radiolanthanide praseodymium-142: a review of production routes, brachytherapy, unsealed source therapy. <i>Annals of Nuclear Medicine</i> , 2011, 25, 529-535.	2.2	30
7	A novel technique for simultaneous diagnosis and radioprotection by radioactive cerium oxide nanoparticles: study of cyclotron production of ^{137m} Ce. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2012, 292, 53-59.	1.5	27
8	Preparation of radioactive praseodymium oxide as a multifunctional agent in nuclear medicine. <i>Nuclear Medicine Communications</i> , 2013, 34, 5-12.	1.1	26
9	Practicality of the cyclotron production of radiolanthanide ¹⁴² Pr: a potential for therapeutic applications and biodistribution studies. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2011, 288, 937-942.	1.5	24
10	Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. <i>European Urology</i> , 2021, 79, 722-733.	1.9	17
11	Production of cationic ¹⁹⁸ Au ³⁺ and nonionic ¹⁹⁸ Au ⁰ for radionuclide therapy applications via the natAu(n, ¹ 3) ¹⁹⁸ Au reaction. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2012, 293, 45-49.	1.5	13
12	Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	13
13	Overview of mercury radionuclides and nuclear model calculations of ¹⁹⁵ Hg, ¹⁹⁷ Hg, and ¹⁹⁹ Hg to evaluate experimental cross section data. <i>Physical Review C</i> , 2012, 85, .	2.9	12
14	Calcium Phosphate Nanoparticles Cytocompatibility Versus Cytotoxicity: A Serendipitous Paradox. <i>Current Pharmaceutical Design</i> , 2017, 23, 2930-2951.	1.9	12
15	Bremsstrahlung parameters of praseodymium-142 in different human tissues: a dosimetric perspective for ¹⁴² Pr radionuclide therapy. <i>Annals of Nuclear Medicine</i> , 2012, 26, 412-418.	2.2	6
16	Radiolabeled nanoceria probes may reduce oxidative damages and risk of cancer: A hypothesis for radioisotope-based imaging procedures. <i>Medical Hypotheses</i> , 2013, 81, 1164-1168.	1.5	6
17	Nuclear model calculations of charged-particle-induced reaction cross section data for the production of the radiohalogen ^{34}Cl . <i>Physical Review C</i> , 2013, 87, .	2.9	6
18	Feasibility study of FLUKA Monte Carlo simulation for a beta-emitting brachytherapy source: dosimetric parameters of ¹⁴² Pr glass seed. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2016, 309, 947-953.	1.5	3

#	ARTICLE	IF	CITATIONS
19	Cyclin-like proteins tip regenerative balance in the liver to favour cancer formation. <i>Carcinogenesis</i> , 2020, 41, 850-862.	2.8	3
20	The Potential Roles of Radionanomedicine and Radioexosomics in Prostate Cancer Research and Treatment. <i>Current Pharmaceutical Design</i> , 2017, 23, 2976-2990.	1.9	3
21	CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2. <i>Cancer Research</i> , 2022, 82, 3088-3101.	0.9	2
22	Monte Carlo simulations and radiation dosimetry measurements of ¹⁴² Pr capillary tube-based radioactive implant (CTRI): a new structure for brachytherapy sources. <i>Annals of Nuclear Medicine</i> , 2013, 27, 253-260.	2.2	1
23	Impact of various color <scp>LED</scp> flashlights and different lighting source to skin distances on the manual and the computerâ€aided detection of basal cell carcinoma borders. <i>Skin Research and Technology</i> , 2014, 20, 92-96.	1.6	1